Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (NYSE:NVO)

During the Trading Day
55.25 +0.28 / +0.51%
As of 4:03pm ET
Day’s Change
During After-Hours   Switch to standard view »
54.85 -0.3973 / -0.72%
Volume: 18.8K
Health Technology
Pharmaceuticals: Major

Company Description

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes Care and Biopharmaceuticals segments. The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of insulin, glucagon-like-peptide 1 and related delivery systems, oral anti-diabetic products, and obesity. The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Contact Information

Novo Nordisk A/S
Novo Allé
Gladsaxe Capital Region 2880
P:(454) 444-8888
Investor Relations:
(453) 075-9085



Other institutional7.12%
Mutual fund holders2.79%
Individual stakeholders--

Top Executives

Lars Rebien SørensenChief Executive Officer
KÃ¥re SchultzPresident & Chief Operating Officer
Jesper BrandgaardChief Financial Officer & Executive Vice President
Mads Krogsgaard ThomsenChief Science Officer & Executive Vice President
Alan C. MosesGlobal Chief Medical Officer